All In Biotech

NDA 012041 · Apothecon

Kenalog-10

Triamcinolone Acetonide · Injection · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1960

Jan 4, 1960

Approved uses

1

Original approval plus efficacy supplements

Registered trials

692

135 Phase 3, 52 recruiting

FAERS reports

26,375

13,659 serious, 3,186 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 30, 2026.

INDICATIONS AND USAGE The intra-articular or soft tissue administration of KENALOG-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of KENALOG-10 Injection is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum.KENALOG-10 Injection may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 4, 1960 Original approval · Type 3 - New Dosage Form
1 products under this application
  • KENALOG-10 · TRIAMCINOLONE ACETONIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 692 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,884
  • off label use2,930
  • pruritus2,762
  • rash2,589
  • pain2,199
  • fatigue2,074
  • nausea1,988
  • product use in unapproved indication1,770
  • diarrhoea1,720
  • vomiting1,716
  • headache1,688
  • condition aggravated1,682

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004145
2005141
2006181
2007146
2008232
2009191
2010195
2011293
2012206
2013228
2014368
2015600
2016789
2017970
20181,175
20191,313
20201,533
20211,813
20222,342
20232,752
20243,567
20253,888
20263,307

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kenalog-10 (Triamcinolone Acetonide)

2024 spending

$6K

Beneficiaries

177

284 claims

Per beneficiary

$37

$2.71 per unit

View as table
YearSpending
2020$7,574
2021$6,853
2022$7,141
2023$6,188
2024$6,473

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 990 on PubMed

Sponsor: Apothecon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.